Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Dianthus Therapeutics (DNTH) over the last 4 years, with Q3 2025 value amounting to $37.8 million.

  • Dianthus Therapeutics' Shares Outstanding (Diluted Average) rose 1039.05% to $37.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.8 million, marking a year-over-year increase of 1039.05%. This contributed to the annual value of $33.3 million for FY2024, which is 54644.12% up from last year.
  • As of Q3 2025, Dianthus Therapeutics' Shares Outstanding (Diluted Average) stood at $37.8 million, which was up 1039.05% from $35.8 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $58.8 million in Q2 2022 and a low of $874234.0 during Q4 2022
  • Moreover, its 4-year median value for Shares Outstanding (Diluted Average) was $33.3 million (2024), whereas its average is $24.5 million.
  • In the last 5 years, Dianthus Therapeutics' Shares Outstanding (Diluted Average) plummeted by 9851.25% in 2023 and then surged by 381210.86% in 2024.
  • Over the past 4 years, Dianthus Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $874234.0 in 2022, then soared by 489.48% to $5.2 million in 2023, then skyrocketed by 546.44% to $33.3 million in 2024, then increased by 13.45% to $37.8 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $37.8 million for Q3 2025, versus $35.8 million for Q2 2025 and $35.8 million for Q1 2025.